FLOXIN OTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLOXIN OTIC (FLOXIN OTIC).
Ofloxacin, a fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
| Metabolism | Ofloxacin undergoes minimal hepatic metabolism; small amounts are metabolized via glucuronidation. The drug is primarily excreted unchanged in urine after systemic absorption; however, otic administration results in negligible systemic concentrations. |
| Excretion | Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (70-80%); non-renal elimination (hepatic metabolism and biliary secretion) accounts for 20-30%. |
| Half-life | 6-8 hours in adults with normal renal function; prolonged to 30-50 hours in severe renal impairment (CrCl <20 mL/min). |
| Protein binding | 20-30% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 2.5-3.0 L/kg; indicates extensive tissue penetration. |
| Bioavailability | Otic: negligible systemic absorption; oral: 90-98%. |
| Onset of Action | For otic use: symptomatic relief within 24-48 hours. |
| Duration of Action | Twice-daily dosing maintains therapeutic concentrations; clinical improvement typically within 3-5 days. |
Instill 5 drops (0.5 mL) into affected ear(s) twice daily for 10-14 days; for acute otitis externa, may use 5 drops twice daily for 7 days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | For children aged 1 year and older: same as adult dosing: 5 drops (0.5 mL) into affected ear(s) twice daily for 10-14 days. |
| Geriatric use | No specific dosage adjustment required; use with caution in elderly patients with pre-existing hearing loss or vestibular disorders. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLOXIN OTIC (FLOXIN OTIC).
| Breastfeeding | Systemic absorption after otic use is negligible; no measurable levels in breast milk. M/P ratio not available. Considered compatible with breastfeeding. |
| Teratogenic Risk | Otic administration results in negligible systemic absorption; therefore, fetal exposure is minimal. No teratogenic effects reported during any trimester. Animal studies show no evidence of harm at doses far exceeding clinical exposure. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning for FLOXIN OTIC. However, systemic fluoroquinolones have a boxed warning for tendinitis, tendon rupture, peripheral neuropathy, CNS effects, and exacerbation of myasthenia gravis; these warnings do not apply to otic use.
| Serious Effects |
["Hypersensitivity to ofloxacin or any component of the formulation","Hypersensitivity to other quinolones (cross-reactivity possible)"]
| Precautions | ["For otic use only; not for ophthalmic or systemic use","Discontinue if sensitization or irritation occurs","Prolonged use may result in overgrowth of non-susceptible organisms, including fungi","Avoid in patients with a known history of hypersensitivity to fluoroquinolones"] |
Loading safety data…
| No specific monitoring required due to minimal systemic absorption. |
| Fertility Effects | No effects on fertility anticipated due to negligible systemic absorption. |